<DOC>
	<DOC>NCT02228655</DOC>
	<brief_summary>FMX-8 is a new type of drug being tested for the treatment of anemia in chronic illnesses.</brief_summary>
	<brief_title>An Exploratory Study to Evaluate FMX-8 to Treat Anemia in CKD</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<criteria>a documented hemoglobin level to be less than 10 g/dL at screening diagnoses of CKD 4 or 5 body mass index (BMI) between 18 kg/m2 and 42 kg/m2, inclusive, based upon the height and weight at screening ferritin levels ≥100 ng/ml or Tsat ≥20% at screening erythropoietin (EPO) level greater than 8 ng/mL able to provide written informed consent able to understand and follow all trial procedures willing to use contraception as detailed in the protocol receipt of red blood cell (RBC) transfusion within four weeks before screening overt gastrointestinal bleeding or other bleeding episode that required transfusion within 2 months prior to screening infection necessitating antibiotic or antiviral treatment within a month prior to screening requiring Coumadin (warfarin), Pradaxa®, Eliquis®, or Xarelto® hemoglobinopathies such as homozygous sicklecell disease or thalassemias of all types active hemolysis or chronic hypoxia active malignant diseases (except nonmelanoma skin cancer) or life expectancy less than 6 months chronic, uncontrolled or symptomatic inflammatory disease or nonrenal cause of anemia such as rheumatoid arthritis, systemic lupus erythematosus, HIV, or systemic acute infection on immunosuppressive therapeutics except topical corticosteroids or nasal sprays chronic congestive heart failure (New York Heart Association Class III, IV) significant hypertension (≥90 diastolic) based on a sitting diastolic blood pressure at screening kidney transplant within the past year: patients who are off immunosuppressive agents following a failed transplant are eligible for the trial endstage liver disease known hypersensitivity to recombinant protein therapies female patients who are pregnant or breast feeding previous exposure to FMX8 previous exposure to Epogen®, Procrit® (erythropoietin) Aranesp® (darbepoietin alpha), Omontys® or Hematide® (peginesatide) anemia treatment uncontrolled hyperparathyroidism (PTH &gt;750) based upon latest PTH determination within the past 4 months inability to comply with the trial scheduled visits</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>CKD</keyword>
	<keyword>Anemia of Chronic Illness</keyword>
</DOC>